Overview of the lenograstim pharmacoeconomics programme.
Lenograstim is a recombinant colony-stimulating factor that has been shown to be a useful adjunctive agent in cancer chemotherapy. Clinical trials have demonstrated the efficacy of lenograstim in correcting chemotherapy-induced neutropenia and associated complications in inflammatory breast cancer and non-Hodgkin's lymphoma, and in facilitating dose intensification of chemotherapy in small cell lung cancer. To meet increasing demands for economic data on new drug entities, a lenograstim pharmacoeconomics programme was established. This programme involved prospective economic evaluations of lenograstim that were undertaken as part of phase III randomised clinical trials by a combined German/Italian health-economics team (inflammatory breast cancer), a French team (non-Hodgkin's lymphoma), and a team from the UK (small cell lung cancer).
Oster
G
G
Policy Analysis Inc., Brookline, Massachusetts, USA.
Menzin
J
J
Richard
D
D
Cour-Chabernaud
V
V
D000276:Adjuvants, Immunologic / Q000737:chemistry / Q000191:economics* / Q000627:therapeutic use; D000595:Amino Acid Sequence; D000970:Antineoplastic Agents / Q000737:chemistry / Q000191:economics* / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D016179:Granulocyte Colony-Stimulating Factor / Q000737:chemistry / Q000191:economics* / Q000627:therapeutic use; D006801:Humans; D000078224:Lenograstim; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000188:drug therapy; D011994:Recombinant Proteins / Q000737:chemistry / Q000191:economics / Q000627:therapeutic use